Related Experiment Videos
[Anticardiolopin antibodies as a risk factor in stroke]
M Krześniak-Bohdan1, L Dobrzyńska, A Bakowska
1Kliniki Neurologii Dorosłych Akademii Medycznej w Gdańsku.
Insights
Anticardiolipin antibodies (aCL) were found in 32.1% of ischemic stroke patients. Higher risk of recurrent ischemic events was observed in aCL-positive individuals, aiding in prognosis.
Area of Science:
- Neurology
- Immunology
- Cardiovascular Medicine
Context:
- Ischemic cerebrovascular disease poses significant health risks.
- Understanding the role of autoimmune markers like anticardiolipin antibodies (aCL) is crucial for stroke patients.
- Previous research indicates potential links between aCL and thrombotic events.
Purpose:
- To investigate the prevalence of anticardiolipin antibodies (aCL) in patients with ischemic cerebrovascular disease.
- To assess the association between aCL presence and the risk of recurrent ischemic events.
- To evaluate the utility of aCL testing in determining the pathogenesis and prognosis of ischemic stroke.
Summary:
- A study examined 53 patients (aged 35-55) with ischemic cerebrovascular disease and 21 healthy controls using ELISA.
- Anticardiolipin antibodies (aCL) were detected in 32.1% of patients, with IgG class antibodies found in 9 individuals.
- A significantly higher risk of recurrent ischemic events was observed in aCL-positive patients (35.3%) compared to aCL-negative patients (5.6%).
Impact:
- The findings suggest that aCL positivity may serve as a risk factor for recurrent ischemic events in stroke patients.
- Detecting aCL can contribute to a better understanding of the disease's pathogenesis.
- aCL testing can aid in identifying patients who may benefit from specific preventative strategies and closer monitoring for improved prognosis.
Abstract:
The level of anticardiolipin antibodies (aCL) in sera of 53 patients with ischemic cerebrovascular disease aged 35-55 years with mean age 48.4 +/- 5.03, was studied using a solid phase enzyme immunosorbent assay (ELISA). The investigation was done half year after the ischemic stroke. The control group consisted of 21 healthy participants matched for age and sex. The presence of aCL was found in sera of 17 persons (32.1%), in 9 it was IgG class antibodies. It was indicated that the risk of repeated cerebral ischemic events was relatively higher in aCL positive patients than in aCL negative. Relapses were found in 6 aCL positive patients (35.3%) (in 5 cases from the group of 9 IgG positive) and in 2 persons (5.6%) aCL negative patients. The existence of aCL can be helpful to determine pathogenesis of the disease and its prognosis.